Looking at SRT from share dilution perspective16 Oct 2023 14:02
This is a cross-post , prompted by comment elsewhere.
... taking a fresh look at things from a different perspective, that of dilution.
SRT started life with 69m shares and an implied MCap of £24m after issuing 11.5m shares @35p.
It now has an MCap of £85m, based on 192m shares and a 44p shareprice.
The history of placings - total 95m shares, raising £ 31.05m at an average of 32.7p- is
-5/2006 9m @47p = £4.25m
-3/2007 9.5m @42p = £4.0m
-4/2012 9.5m @27p = £2.5m
-7/2014 8.5m @ 18p = £1.5m
-5/2018 12m @25p = £3.0m
-1/2019 13.4m @30p = £4.0m
-4/2020 6.0m @25p = £1.5m
-3/2022 16.4m @30p = £4.9m
-6/2023 10.7m @50p = £5.4m
There's been further dilution of (192 -(69+95)= 28m shares, through a mix of options and warrant exercise that will have raised a bit more cash.
Meanwhile, the Loan Note Facility has grown progressively, from an initial £ 10m in 9/2017 to the recently-increased (3/2023)£ 40m.
As shareholders/owners - we should recognise that the LNF has so far reduced the immediate need for further dilution.
OTOH, these secured loans come at a price, not only in interest but also operational flexibility : the March 2023 breach of covenants in relation to debt service cover and gearing was only cured, AFAICS , by the latest placing.
SRT reported gross cash balances of £3.9m @ 30 September 2023 (historically about £900K of this has been restricted), at 3/2023 it was £ 2.2m gross and the LNF stood at £ 7.7m.
On the face of it, this affords reasonable headroom, depending on covenant test definitions.
Timely progress re: project execution, client acceptance, invoicing and payment - all remain pretty critical, though.
Corrections and clarifications more than welcome!
ATB
ATB